Merck KGaA (DE:MRK)
XETRA:MRK
Want to see DE:MRK full AI Analyst Report?
MRK Stock Chart & Stats
€118.50
-€0.25(-0.17%)
At close: 4:00 PM EST
€118.50
-€0.25(-0.17%)
Day’s Range― - ―
52-Week Range€100.70 - €140.25
Previous CloseN/A
Volume8.13K
Average Volume (3M)321.00K
Market Cap
€57.93B
Enterprise Value€66.19B
Total Cash (Recent Filing)€2.74B
Total Debt (Recent Filing)€12.04B
Price to Earnings (P/E)22.9
Beta0.98
Next Earnings
Aug 06, 2026Next Dividend Ex-DateN/A
Dividend Yield1.82%
Share Statistics
EPS (TTM)5.82
Shares Outstanding129,242,250
10 Day Avg. Volume344,164
30 Day Avg. Volume321,004
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)1.86
Price to Sales (P/S)2.53
P/FCF Ratio22.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€136.88Price Target Upside15.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)7.96
Revenue Forecast (FY)€21.06B
Bulls Say, Bears Say
Bulls Say
Durable MarginsSustained high gross and operating margins across periods indicate structural pricing power and cost efficiency in core businesses. That margin durability cushions earnings during top-line softness, funds R&D and capex, and supports longer-term free cash generation even if revenue growth slows.
Business Diversification & Recurring SalesA three-segment model with recurring consumables in Life Science reduces revenue cyclicality and provides predictable annuity-like demand. Exposure to healthcare and electronics adds secular end-market diversity, lowering reliance on any single product cycle and supporting steadier medium-term revenue streams.
Manageable Leverage / Balance Sheet ResilienceModerate and improving leverage gives financial flexibility for R&D, capex, or targeted M&A without overburdening cash flow. A stronger equity base and controlled debt levels support credit stability and the ability to absorb near-term earnings volatility without forcing asset sales or dramatic capital-structure shifts.
Bears Say
Weak Revenue MomentumStagnant then declining top-line reduces operating leverage and pressures long-term growth outlook. Without clear new-product lift or faster end-market recovery, weaker revenues risk margin erosion over time, limit reinvestment capacity, and make meeting investor growth expectations harder.
Cooling Returns On EquityA multi-point drop in ROE signals less efficient capital use or slower profit generation from the asset base. Persistently lower ROE can undermine long-term shareholder value creation, constrain dividend growth potential, and indicate competitive or pricing pressures that are structurally reducing profitability.
Moderate Cash ConversionOnly moderate conversion of accounting profits to free cash limits internal funding for R&D, dividends, or bolt-on M&A without tapping capital markets. If margins slip or capex needs rise, constrained cash conversion increases refinancing or external funding risk and reduces balance-sheet optionality.
MRK FAQ
What was Merck KGaA’s price range in the past 12 months?
Merck KGaA lowest stock price was €100.70 and its highest was €140.25 in the past 12 months.
What is Merck KGaA’s market cap?
Merck KGaA’s market cap is €57.93B.
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is Aug 06, 2026 which is in 53 days.
How were Merck KGaA’s earnings last quarter?
Merck KGaA released its earnings results on May 13, 2026. The company reported €2.11 earnings per share for the quarter, beating the consensus estimate of €1.947 by €0.163.
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Undervalued.
Does Merck KGaA pay dividends?
Merck KGaA pays a Annually dividend of €2.2 which represents an annual dividend yield of 1.82%. See more information on Merck KGaA dividends here
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is 2.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Merck KGaA reported an EPS of €2.11 in its last earnings report, beating expectations of €1.947. Following the earnings report the stock price went up 7.212%.
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in DE:MRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€136.88 (15.51% Upside)
€136.88 (15.51% Upside)
Insider Transactions
Bought Shares
Worth €823.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.96%
12-Months-Change
Fundamentals
Return on Equity
8.77%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Merck KGaA
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
MRK Stock 12 Month Forecast
Average Price Target
€136.88
▲(15.51% Upside)
Technical Analysis
Evotec
―
Fresenius SE & Co. KGaA
―
Sartorius
―
Dermapharm Holding SE
―
Siemens Healthineers AG
―
Options Prices
Currently, No data available
---